GO FOR the GOLD DEVICE1
Fixed dose triple therapy in a pMDI for patients with moderate to very severe COPD
SCAN TO ORDER BREZTRI ® SAMPLE
INDICATION : BREZTRI AEROSPHERE ® is indicated as a maintenance treatment to prevent exacerbations and relieve symptoms in adults with moderate , severe , or very severe COPD who require treatment with a combination of ICS , LABA , and LAMA . 1
BREZTRI AEROSPHERE ® is not indicated for the initiation of therapy in COPD . 1
SAFETY : In ETHOS , adverse events that occurred in ≥3 % of patients overall for BREZTRI ® and GLY / FORM were nasopharyngitis , COPD , upper respiratory tract infection , pneumonia and bronchitis . 2 The incidence of confirmed pneumonia was 4.2 % with BREZTRI ® and 2.3 % with GLY / FORM . 1 , 2 Please review Product Information for information on other Precautions and Adverse Effects .
PBS Information : Authority required ( STREAMLINED ) for the treatment of COPD . Refer to PBS for full authority information .
PLEASE REVIEW FULL PRODUCT INFORMATION BEFORE PRESCRIBING . PRODUCT INFORMATION AVAILABLE ON REQUEST FROM ASTRAZENECA ON 1800 805 342 OR WWW . ASTRAZENECA . COM . AU / PI OR BY SCANNING THIS QR CODE .
SCAN QR CODE to see full BREZTRI ® Product Information
COPD = chronic obstructive pulmonary disease ; FORM = formoterol ; GLY = glycopyrronium ; ICS = inhaled corticosteroid ; LABA = long-acting beta 2 agonist ; LAMA = long-acting muscarinic antagonist ; pMDI = pressurised Metered Dose Inhaler . References : 1 . BREZTRI AEROSPHERE ® Approved Product Information . 2 . Rabe F et al . N Engl J Med . 2020 ; 383 ( 1 ): 35 – 48 .
BREZTRI ® and AEROSPHERE ® are registered trademarks of the AstraZeneca group of companies . Registered user AstraZeneca Pty . Ltd . ABN 54 009 682 311 . 66 Talavera Road , Macquarie Park , NSW 2113 . www . astrazeneca . com . au . For Medical Information enquiries or to report an adverse event or product quality complaint : Telephone 1800 805 342 or via https :// contactazmedical . astrazeneca . com . 002512 . 2743 . AU-21579 . January 2025 .